GORD208 · MTAP-deleted tumors
Out-licensed to Kohde Pharma. Targets identified through patient-derived dependency mapping and not detectable in standard cell-line models. MTAP deletions occur in ~15% of cancers; no targeted therapy is approved.
Pipeline
Bispecifics for genetically defined populations
Each program inhibits a primary target and its compensatory mechanism at the same time. The aim is a higher response rate and a lower risk of resistance, in a population we can define from the data.
| Program | Modality | Population | Status | Rationale |
|---|---|---|---|---|
| GORD208 | Undisclosed target | MTAP-deleted tumors | Licensed to Kohde Pharma | ~15% of all cancers carry an MTAP deletion; no targeted therapy approved |
| GORD132 | MET bispecific antibody | MET-amplified tumors | In house | Primary target plus compensatory mechanism in one molecule |
| GORD167 | Undisclosed bispecific antibody | PD-L1 non-responders | In house | Patients who do not respond to PD-L1 blockade |
GORD132 · MET bispecific
MET bispecific antibody for MET-amplified tumors. Partnering discussions open.
GORD167 · PD-L1 non-responders
Undisclosed bispecific antibody for patients who do not respond to PD-L1 blockade.